# Protocol: Care Transition Interventions to Reduce 30-Day Readmission in Heart Failure: A Systematic Review

**Review ID:** demo-chf-care-transitions
**Date:** 2026-06-24
**Review Type:** Systematic Review
**Status:** Illustrative demo — derived from a real, larger review; included set trimmed to 6 open-access articles for repository documentation purposes only.

## 1. Background and Rationale

Heart failure (HF) is among the leading causes of hospital readmission in the United States, with 30-day all-cause readmission rates consistently ranging from 20–25% nationally. Under the Hospital Readmissions Reduction Program (HRRP), CMS applies financial penalties to hospitals with excess readmissions for HF, creating strong regulatory and financial incentives to reduce this metric. Beyond the financial implications, preventable HF readmissions represent a failure of care continuity that carries meaningful consequences for patient morbidity, quality of life, and mortality.

The care transition period — the 30 days immediately following hospital discharge — is recognized as the highest-risk window for HF patients. Physiologic instability, medication complexity, dietary nonadherence, and delayed outpatient follow-up converge during this period. A growing body of literature has examined care transition interventions designed to bridge this gap, ranging from structured discharge education and medication reconciliation to remote telemonitoring, transitional care nurse models, and early post-discharge follow-up. However, the evidence base is heterogeneous in both intervention design and reported outcomes, making it difficult for health systems to identify which interventions yield the greatest readmission reduction and whether their benefits are generalizable to community hospital settings.

This systematic review is motivated by a specific operational need: to identify and prioritize evidence-based care transition interventions suitable for implementation at a community acute care hospital seeking to reduce its HF 30-day readmission rate. The review will synthesize intervention effectiveness, characterize the magnitude of readmission reduction, and — where evidence permits — describe the resource intensity and implementation complexity associated with each intervention type to support local prioritization.

## 2. Objectives

To systematically evaluate the effectiveness of care transition interventions initiated at or around hospital discharge — compared with usual care — in reducing 30-day all-cause and HF-specific hospital readmission rates among adult patients (≥18 years) hospitalized with heart failure (any ejection fraction).

## 3. Eligibility Criteria

### Inclusion Criteria
- Adult patients (≥18 years) with a primary diagnosis of heart failure (HFrEF, HFpEF, or HFmrEF; any NYHA class)
- Index hospitalization for acute decompensated heart failure or with heart failure as the primary discharge diagnosis
- Intervention initiated at or closely around hospital discharge (within 7 days of discharge date)
- Intervention type includes at least one of: early outpatient follow-up (cardiology or primary care within 7–14 days), transitional care model, nurse- or pharmacist-led discharge education, remote monitoring or telemonitoring, post-discharge telephone follow-up, home health or home visit program, patient navigation, medication reconciliation program, or multidisciplinary transitional care team
- Comparator: usual care (standard discharge without a structured transition program)
- Reports 30-day all-cause readmission, 30-day HF-specific readmission, or a closely related readmission endpoint as a primary or secondary outcome
- Study design: randomized controlled trial (RCT), systematic review, meta-analysis, or prospective observational study with a concurrent comparator group
- Full text available in English
- Published January 2000 or later

### Exclusion Criteria
- Pediatric populations (<18 years): HF pathophysiology and management differ substantially
- Interventions initiated exclusively >7 days post-discharge with no peri-discharge component: these represent chronic disease management rather than care transitions
- Studies reporting inpatient management strategies only, without a post-discharge follow-up component
- Studies that do not report a readmission outcome (e.g., studies reporting only symptom burden or biomarker outcomes)
- Case reports, editorials, letters, narrative commentaries, and conference abstracts without original data
- Populations dominated by post-cardiac transplant or LVAD-dependent patients, where care transition structure and readmission drivers differ fundamentally from general HF
- Non-English language publications (resource constraints preclude translation for this review)

## 4. Information Sources

The following databases will be searched:
- **PubMed/MEDLINE** — primary biomedical database; MeSH-controlled vocabulary + free-text strategy
- **OpenAlex** — broad academic coverage including grey literature and preprints
- **Semantic Scholar** — AI-assisted relevance ranking; strong coverage of clinical informatics and implementation science literature
- **Europe PMC** — European clinical trial registry coverage and grey literature

Handsearching of reference lists of included systematic reviews will be performed during citation chasing (Stage 8.5). Grey literature from CMS, AHRQ, and ACC/AHA will be considered for contextual evidence on implementation but will not be included as primary study evidence.

## 5. Search Strategy

Search strategy will be constructed after protocol approval using MeSH controlled vocabulary and free-text terms per PICO aspect. Key MeSH terms will include: Heart Failure [Mesh], Patient Discharge [Mesh], Patient Readmission [Mesh], Transitional Care [Mesh], Telemedicine [Mesh], Patient Navigation [Mesh], Medication Reconciliation [Mesh]. Free-text synonyms will cover HF subtypes, intervention categories, and readmission terminology. Full stepwise PubMed query history will be documented in `search_log.md` upon completion of Stage 4 (Query Construction). Year filter: 2000–present.

## 6. Selection Process

All retrieved records will undergo dual-pass LLM-assisted abstract screening using PICO inclusion and exclusion criteria. Batches of 20 abstracts will be processed per conversation turn with an explicit decision (include/exclude/borderline) and a reason for each decision. Borderline articles will be flagged for human review and carried forward to full-text eligibility assessment. Full-text PDFs will be obtained for all articles passing abstract screening. Full-text eligibility will be assessed against all inclusion/exclusion criteria, with rationale documented for each exclusion. Discrepancies will be resolved by physician advisor review.

## 7. Data Extraction Plan

Structured data will be extracted for all included articles:
- Study design and NHMRC evidence level
- Sample size (N)
- Follow-up duration
- Intervention description (type, components, timing, provider, intensity)
- Comparator description
- Primary outcome: 30-day all-cause readmission rate with effect size, 95% CI, and p-value
- Secondary outcomes as reported
- Author conclusions
- Funding source
- Conflict of interest declaration

Data will be stored in a structured evidence table (`evidence_table.csv`).

## 8. Quality Appraisal Plan

Quality appraisal instruments will be selected by study type:
- **Systematic reviews and meta-analyses:** AMSTAR-2
- **RCTs:** Cochrane Risk of Bias 2.0 (RoB 2.0)
- **Prospective observational studies:** STROBE checklist

All appraisals will be documented in `quality_report.md`. Studies scoring below 0.5 on the normalized quality scale will be flagged and their contribution to conclusions noted with appropriate caution.

## 9. Synthesis Method

Narrative synthesis will be the primary approach, organized by PICO outcome and intervention category. For each intervention type, findings will be described in terms of direction of effect, magnitude, and consistency across studies. If three or more studies report the same outcome using compatible metrics and statistical heterogeneity is acceptable (I² < 60%), a quantitative meta-analysis using a random-effects model will be considered. Evidence will be graded using the NHMRC hierarchy (Level I–IV). Intervention feasibility and implementation complexity will be summarized descriptively to support local prioritization.

## 10. Protocol Registration

This protocol was registered internally prior to search commencement. For reviews intended for journal submission or formal dissemination, PROSPERO registration (prospero.york.ac.uk) is recommended. The protocol is locked as of 2026-06-24 and cannot be modified after this date.

---

**Note on this demo:** This protocol, PICO, and search strategy are real and unmodified from the
underlying review this demo was derived from. What differs is the included-article set: it has
been trimmed to 6 open-access articles (from a much larger real included set) and the PRISMA
counts have been replaced with small illustrative placeholder numbers, so this repository can
ship a complete example `/lit-review` output folder without redistributing copyrighted abstract
text or a large private evidence base.
